The Dermatological Manifestations in the Coronavirus Infection COVID-19
https://doi.org/10.20514/2226-6704-2020-10-6-422-429
Abstract
The variety of dermatological manifestations in patients with the novel coronavirus infection COVID-19, the incidence of which depends on concomitant pathology and the characteristics of drug treatment, and their characteristics are similar to those that occur with conventional viral infections is discussed. At the present time it is proposed to distinguish several groups depending on the cause and mechanism of development: angiitis of the skin; papulo-squamous rash and pink lichen; measles rash and infectious erythema; papulo-vesicular rash; toxidermia; urticarial eruptions and artifical lesions. The variety of the clinical picture of the skin manifestations of coronavirus infection requires in-depth analysis in order to interpret correctly the skin lesions and other infectious exanthema and dermatoses in patients with COVID-19.
About the Authors
A. S. Dvornikov
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Moscow
Russian Federation
Moscow
A. A. Silin
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Moscow
Russian Federation
Moscow
T. A. Gaydina
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Russian Federation
Tatiana A. Gaydina
Moscow
V. N. Larina
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Moscow
Russian Federation
Moscow
P. A. Skripkina
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Moscow
Russian Federation
Moscow
E. V. Kiva
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Moscow
Russian Federation
Moscow
References
1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report — 95. 2020. [Electronic resource]. URL:https://www.who.int/docs/default-source/coronaviruse/situationreports/20200424-sitrep-95-covid-19.pdf?sfvrsn=e8065831_4. (date of the application: 07 Nov 2020)
2. Temporary methodical recommendations prevention. diagnostics and treatment of a new coronavirus infections (COVID-19) of the Ministry of health of the Russian Federation (version 8.1 (01.10.2020)) [Electronic resource]. URL: https://www.rosminzdrav.ru/ministry/med_covid19. (date of the applicatioт: 07 Nov 2020) [In Russian].
3. Guan W.J., Ni Z.Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708-1720. doi:10.1056/NEJMoa2002032.
4. Potekaev N.N., Zhukova O.V., Protsenko D.N. et al. Clinical characteristics of dermatologic manifestations of COVID-19 infection: case series of 15 patients, review of literature, and proposed etiological classification. Int J Dermatol. 2020; 59(8):1000-1009. doi:10.1111/ijd.15030.
5. Ortega-Quijano D., Jimenez-Cauhe J., Selda-Enriquez G. et al. Algorithm for the classification of COVID-19 rashes. J Am Acad Dermatol. 2020; 83(2):e103-e104. doi:10.1016/j.jaad.2020.05.034.
6. De Giorgi V., Recalcati S., Jia Z. et al. Cutaneous manifestations related to corona virus disease 2019 (COVID-19): A prospective study from China and Italy. J Am Acad Dermatol. 2020; 83(2):674-675. doi: 10.1016/j.jaad.2020.05.073.
7. Su C.J., Lee C.H. Viral exanthem in COVID-19, a clinical enigma with biological significance. J EurAcadDermatolVenereol. 2020; 34(6):e251-e252. doi: 10.1111/jdv.16469.
8. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020; 34(5): e212-e213. doi: 10.1111/jdv.16387.
9. Marzano A.V., Genovese G., Fabbrocini G. et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020; 83(1):280-285. doi: 10.1016/j.jaad.2020.04.044.
10. Joob B., Wiwanitkit V. Hemorrhagic problem among the patients with COVID-19: clinical summary of 41 Thai infected patients. Clin Appl Thromb Hemost. 2020; 26: 1076029620918308. doi:10.1177/1076029620918308.
11. Henry D., Ackerman M., Sancelme E. et al. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020; 34(6):e244-e245. doi: 10.1111/jdv.16472.
12. Zhang Y., Cao W., Xiao M. et al. Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and ac ro-ischemia. ZhonghuaXue YeXueZaZhi. 2020; 41(4): 302-307. doi: 10.3760/cma.j.issn.0253-2727.2020.008.
13. Kanitakis J., Lesort C., Danset M. et al. Childblain-like acral lesions during the C OVID-19 pandemic (“COVID toes”): Histologic, immunofluorescence and immunohistochemical study of 17 cases. J Am Acad Dermatol. 2020; 83(3):870-875. doi: 10.1016/j.jaad.2020.05.145.
14. Jia J.L., Kamceva M., Rao S.A. et al. Cutaneous manifestations of COVID-19: A preliminary review.J Am Acad Dermatol. 2020; 83(2):687-690. doi:10.1016/j.jaad.2020.05.059.
15. Vesely M.D., Perkins S.H. Caution in the time of rashes and COVID-19. J Am AcadDermatol. 2020; 83(4): e321-e322. doi: 10.1016/j.jaad.2020.07.026.
16. Roncati L., Ligabue G., Fabbiani L. et al. Type 3 hypersensitivity in COVID-19 vasculitis.ClinImmunol . 2020; 217: 108487. doi:10.1016/j.clim.2020.108487.
17. Galvan Casas C., Catala A., Carretero Hernandez G. et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br. J. Dermatol. 2020; 183(1):71-77. doi: 10.1111/bjd.19163.
18. Mazzotta F, Troccoli T. Acute acro-ischemia in the child at the time of COVID-19. Eur. J. Ped. Dermatol.2020; 30(2): 71–74.doi: 10.26326/2281-9649.30.2.2102.
19. Kolivras A., Dehavay F., Delplace D., et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathological findings. JAAD Case Reports. 2020; 6(6): 489-492. doi: 10.1016/j.jdcr.2020.04.011.
20. Dursun R, Temiz SA. The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasisrosea and Kawasaki. Dermatol Ther. 2020;e13730. doi:10.1111/dth.13730.
21. Kang J.H. Febrile illness with skin rashes. Infect Chemother. 2015; 47(3): 155-166.doi:10.3947/ic.2015.47.3.155.
22. Hedou M., Carsuzaa F., Chary E. et al. Comment on “Cutaneous manifestations in COVID-19: a first perspective” by Recalcati S. J Eur Acad Dermatol Venereol. 2020; 34(7): e299-e300. doi: 10.1111/jdv.16519.
23. Jones V.G., Mills M., Suarez D. et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr. 2020; 10(5): 537-540. doi: 10.1542/hpeds.2020-0123.
24. Luchsheva V.I., Zharova S.N., Nikiforova V.V. Atlas of infectious diseases. Izdatelskaya gruppa «GEOTAR-Media». 2014; 224 p. [in Russian].
25. Tammaro A., Adebanjo G.A.R., Parisella F.R. et al. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol. 2020; 34(7): e306-e307. doi: 10.1111/jdv.16530.
26. Van Damme C., Berlingin E., Saussez S. et al. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020; 34(7): e300-e301. doi: 10.1111/jdv.16523.
27. Joob B., Wiwanitkit V. COVID-19 in medical personnel: observation from Thailand. J Hosp Infect. 2020; 104(4): 453. doi: 10.1016/j.jhin.2020.02.016.
28. Elston D.M. Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic. J Am Acad Dermatol. 2020; 82(5): 1085-1086. doi: 10.1016/j.jaad.2020.03.012.
29. Schwartz R.A., Reynoso-Vasquez V., Kapila R. Chloronychia: the Goldman-fox syndrome: implications for patients and health care workers. Indian J Dermatol. 2020; 65(1): 1-4. doi: 10.4103/ijd.IJD_277_19.
30. Soria A., Barbaud A., Assier H. et al. Cutaneous adverse drug reactions with antimalarials and allergological skin tests. Dermatology.2015; 231(4): 353-359. doi: 10.1159/000438787.
31. Wang C., Rademaker M., Baker C. et al. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australia/New Zealand consensus statement. Australas J Dermatol. 2020; 61(3): 210-216. doi: 10.1111/ajd.13313.
32. Wollenberg A., Flohr C., Simon D. et al. European task force on atopic dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. J EurAcad Dermatol Venereol. 2020; 34(6): e241-e242. doi: 10.1111/jdv.16411.
33. Schwartz R.A., Kapila R. Cutaneous manifestations of a 21st century worldwide fungal epidemic possibly complicating the COVID-19 pandemic to jointly menace mankind. DermatolTher. 2020; 33(4): e13481. doi: 10.1111/dth.13481.
34. Van Doremalen N., Bushmaker T., Morris D.H. et al. Aerosol and surfacestability of SARS-CoV-2 as compared with SARSCoV-1. N Engl J Med. 2020; 382(16): 1564-1567. doi: 10.1056/NEJMc2004973.
35. Russian society of dermatovenerologists and cosmetologists Clinical guidelines the Ministry of health of the Russian Federation”Toxicoderma”.2016; 26p. [in Russian].
36. Tairova R.T., Gaydina T.A., Dvornikov A.S. et al. Difficulties in differential diagnosis of skin manifestations in coronavirus infection. Vestnik RGMU. 2020; 5: 72-78. doi: 10.24075/vrgmu.2020.062. [in Russian].
37. Verduyn M., Allou N., Gazaille V. et al. Co-infection of dengue and COVID-19: A case report. PLoS Negl Trop Dis. 2020; 14(8): e0008476. doi: 10.1371/journal.pntd.0008476.
38. Sun J., Aghemo A., Forner A. et al. COVID-19 and liver disease. Liver Int. 2020; 40(6): 1278–1281. doi: 10.1111/liv.14470.
39. Lucas C., Wong P., Klein J. et al. Longitudinal analyses reveal immunological misfiring in se vere COVID-19. Nature. 2020; 584(7821): 463-469. doi: 10.1038/s41586-020-2588-y.
40. Gu J., Han, B., Wang J. COVID-19: gastrointestinal manifestations and poten tial fecal–oral transmission. Gastroenterology. 2020; 158(6): 1518-1519. doi: 10.1053/j.gastro.2020.02.054.
41. Ivashkin V.T., Sheptulin A.A., Zolnikova O.Yu. et al. New Coronavirus Infection (COVID-19) and Digestive System. Russian Jou rnal of Gastroenterology, Hepatology, Coloproctology. 2020; 30(3): 7-13. doi: 10.22416/1382-4376-2020-30-3-7. [in Russian]
Review
For citations:
Dvornikov A.S., Silin A.A., Gaydina T.A., Larina V.N., Skripkina P.A., Kiva E.V. The Dermatological Manifestations in the Coronavirus Infection COVID-19. The Russian Archives of Internal Medicine. 2020;10(6):422-429. https://doi.org/10.20514/2226-6704-2020-10-6-422-429
Views:
1563
Email this article 